Last reviewed · How we verify
Cetuximab wkly
Cetuximab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation and survival.
Cetuximab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation and survival. Used for Metastatic colorectal cancer (KRAS wild-type), Head and neck squamous cell carcinoma, Non-small cell lung cancer (EGFR-expressing).
At a glance
| Generic name | Cetuximab wkly |
|---|---|
| Also known as | Erbitux |
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | EGFR inhibitor (monoclonal antibody) |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cetuximab binds to EGFR on the surface of cancer cells, preventing ligand-induced receptor activation and downstream signaling through the MAPK and PI3K/AKT pathways. This leads to cell cycle arrest and apoptosis. The weekly formulation (cetuximab wkly) refers to a dosing schedule optimized for patient convenience while maintaining therapeutic efficacy.
Approved indications
- Metastatic colorectal cancer (KRAS wild-type)
- Head and neck squamous cell carcinoma
- Non-small cell lung cancer (EGFR-expressing)
Common side effects
- Acneiform rash
- Diarrhea
- Nausea
- Fatigue
- Infusion reactions
- Hypomagnesemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |